The Inaccuracy of Patient Recall for COPD Exacerbation Rate Estimation and Its Implications: Results from Central Adjudication.
暂无分享,去创建一个
L. Held | M. Puhan | G. ter Riet | A. Frei | A. Strassmann | M. Zoller | L. Siebeling | P. Muggensturm | Callista Wolters | Alexandra Strassmann
[1] M. Puhan,et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. , 2014, Journal of clinical epidemiology.
[2] David R. Gagnon,et al. Daily Step Count Predicts Acute Exacerbations in a US Cohort with COPD , 2013, PloS one.
[3] M. Puhan,et al. Simple functional performance tests and mortality in COPD , 2013, European Respiratory Journal.
[4] Mark Woodward,et al. Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial , 2013, PloS one.
[5] Dacheng Liu,et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. , 2012, Respiratory medicine.
[6] W. Xiong,et al. Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis , 2012, Journal of clinical pharmacy and therapeutics.
[7] M. Puhan,et al. Characteristics of Dutch and Swiss primary care COPD patients – baseline data of the ICE COLD ERIC study , 2011, Clinical epidemiology.
[8] A. Schrijvers,et al. The impact of using different symptom-based exacerbation algorithms in patients with COPD , 2011, European Respiratory Journal.
[9] N. Leidy,et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. , 2011, American journal of respiratory and critical care medicine.
[10] Dirkje S Postma,et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? , 2009, Chest.
[11] S. Yusuf,et al. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs , 2009, Clinical trials.
[12] M. Woodward,et al. Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) , 2009, Stroke.
[13] Gerben ter Riet,et al. BMC Pulmonary Medicine BioMed Central Study protocol Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT , 2009 .
[14] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[15] M Cazzola,et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.
[16] F. Maltais,et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials , 2007, Thorax.
[17] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[18] Robert A Wise,et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.
[19] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[20] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[21] C. Kooperberg,et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.
[22] H. Schünemann,et al. Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study. , 2004, Respiratory medicine.
[23] A. Pont,et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.
[24] G. Guyatt,et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. , 2003, Journal of clinical epidemiology.
[25] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[26] R. Califf,et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial , 2001, Current controlled trials in cardiovascular medicine.
[27] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[28] M Dosemeci,et al. Non-differential misclassification and bias towards the null: a clarification. , 1995, Occupational and environmental medicine.
[29] G. Guyatt,et al. A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.
[30] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.
[31] C Brownie,et al. The effects of exposure misclassification on estimates of relative risk. , 1986, American journal of epidemiology.